title: Management consideration in nonpulmonary visceral metastatic seminoma of testis.
abstract: To develop a more appropriate therapeutic strategy for treatment of nonpulmonary visceral metastatic testicular seminoma based on the International Germ Cell Consensus Classification, we reviewed the medical records of patients with nonpulmonary visceral metastatic testicular seminoma who were treated over a 20-year period. Only 15 (2.2%) of the 686 cases of testicular seminoma were nonpulmonary visceral metastatic seminoma. The median age of patients was 38 years (range, 22-53 years). Ten (67%) of the patients had an initial diagnosis of supradiaphragmatic or visceral metastatic disease. In addition to nonpulmonary visceral metastasis, all patients had lymph node metastasis as well, the majority of which involved the retroperitoneal lymph nodes. The median and mean progression-free survival durations after chemotherapy for advanced disease were 19 months and 63.7 months, respectively. Six patients (40%) survived, five relapsed after radiation therapy and four died of chemorefractory disease not dependent on the specific regimen. Although the number of cases reviewed in this study was small, we conclude that the choice of chemotherapeutic regimen among the current treatments for nonpulmonary visceral metastatic seminoma of testis primary does not present a different outcome. Therefore, multimodality therapies using new strategies or new agents are well indicated.
authors.affiliation: Department of Urology, Pundang CHA Hospital, Pochon CHA University, Sungnam, Korea. dsparkmd@netsgo.com
authors.forename: D S
authors.initials: DS
authors.lastname: Park
authors.forename: D M
authors.initials: DM
authors.lastname: Prow
authors.forename: R J
authors.initials: RJ
authors.lastname: Amato
authors.forename: C J
authors.initials: CJ
authors.lastname: Logothetis
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D003131:Combined Modality Therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000532:radiotherapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D012189:Retrospective Studies; D018239:Seminoma / Q000188:drug therapy* / Q000532:radiotherapy / Q000556:secondary*; D013736:Testicular Neoplasms / Q000473:pathology*